A study on pharmacokinetics, pharmacodynamics and safety of lixisenatide in children and adolescents with type 2 diabetes
Sign Up to like & getrecommendations! Published in 2022 at "Pediatric Diabetes"
DOI: 10.1111/pedi.13343
Abstract: The aim of this study was to investigate the pharmacokinetic, pharmacodynamic and safety profile of the glucagon‐like peptide‐1 receptor agonist, lixisenatide, for the treatment of type 2 diabetes (T2D) in pediatric individuals. read more here.
Keywords: safety; pharmacokinetics pharmacodynamics; diabetes study; pharmacodynamics safety ... See more keywords